Fred Alger Management, LLC Immunovant, Inc. Transaction History

Fred Alger Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $16.7 Million - $21 Million	-664,038 Reduced 52.21%	607,724 $16 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $11.7 Million - $16.9 Million	386,890 Added 43.72%	1,271,762 $41.1 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $9.43 Million - $13.3 Million	-301,159 Reduced 25.39%	884,872 $37.3 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $21.6 Million - $46.6 Million	1,166,929 Added 6108.94%	1,186,031 $45.5 Million
Q2 2023 Aug 14, 2023	SELL	$14.2 - $23.75 $146,842 - $245,598	-10,341 Reduced 35.12%	19,102 $362,000
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $449,594 - $580,615	29,443 New	29,443 $456,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.